


# Liquid rFGF-2 Formulations

## CN-RP-HPLC

### % Main Peak

### 4°C



**Figure 1**

# rFGF-2 Liquid Formulations

## CN-RP-HPLC

### % Main Peak

### 17°C





Figure 2



### Figure 3

# Liquid rFGF-2 Formulations % Main Peak CN-RP-HPLC 30°C




Figure 4


Title: Stabilized FGF Formulations Containing Reducing Agents  
Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa  
Application No: PP16021.002 (35784213736)  
Att. Dkt. No:

# Lyophilized rFGF-2 Formulations

## CN-RP-HPLC

### % Main Peak

### 40°C



**Figure 5**

All formulations contain:

10 mM sodium citrate  
2% glycine  
1% sucrose  
1 mM EDTA

Title: Stabilized FGF Formulations Containing Reducing Agents  
Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa  
Application No: Not yet assigned  
Atty Dkt No: PPI6021.002 (35784/213736)


# Lyophilized rFGF-2 Formulations

## CN-RP-HPLC

### % Main Peak

### 50°C

Title: Stabilized FGF Formulations Containing Reducing Agents  
 Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa  
 Application No: Not yet assigned  
 Atty Dkt No: PP 16021.002 (35784/213736)



Weeks

Figure 6

All formulations contain:

10 mM sodium citrate  
 2% glycine  
 1% sucrose  
 1 mM EDTA

- 0% Acetyl Cysteine / 0 mM DTT pH 5.5
- 0.5% Acetyl Cysteine pH 5.5
- ▲ 10 mM DTT pH 5.5
- ▼ 0.5% Acetyl Cysteine / 10 mM DTT pH 5.5
- ◆ 0.5% Acetyl Cysteine pH 6.0
- 10 mM DTT pH 6.0
- 0.5% Acetyl Cysteine / 10 mM DTT pH 6.0
- △ 0.5% Acetyl Cysteine pH 6.5
- ▽ 10 mM DTT pH 6.5
- ◇ 0.5% Acetyl Cysteine / 10 mM DTT pH 6.5

# rhFGF2 Stability 30°C RP-HPLC % Main Peak




Figure 7